Lincoln Pharmaceuticals Ltd
LINCOLNLincoln Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 69th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (26 weeks in) while the P/E sits at the 69th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +28.6% year on year, and 100% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Lincoln Pharmaceuticals Ltd trades at ₹624, in a confirmed uptrend and 26 weeks into that stage. That is +4.2% against its own 200-day average. It sits at 61% of a 52-week range of ₹453 to ₹734. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a confirmed uptrend — week 26 of stage 2, confirmed. At ₹624 it trades +4.2% versus its 200-day average and sits at 61% of its 52-week range (₹453–₹734).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +321% while the NIFTY 500 moved +273% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Lincoln Pharmaceuticals Ltd's story is not scored yet against the markers our research file set on 17 May 2026. Where it sits in its own cycle: NEAR_PEAK. Still open: EBITDA margin target cut 20-22% → 15-18%; TGA market entry failed and restarted; Cepha Rs 55-65 Cr → Rs 45 Cr — three material revisions in two years erode conviction.
Our read, 17 May 2026. A small-cap formulator transitioning from Africa-led exports to regulated markets — Cepha block and Health Canada SRA are the re-rating levers, but management's guidance credibility is under pressure.
From the numbers. PE at 83rd percentile of 10-year range — NEAR_PEAK cycle signal. Current PE 14.7x is above the 10Y median of 11.2x (ratio 1.23x) with INFLECTION_UP YoY trend. DII buying is the institutional signal per…
From the price. Price stage 2, week 26 — above its 200-day line, relative strength rising.
From the research. A small-cap formulator transitioning from Africa-led exports to regulated markets — Cepha block and Health Canada SRA are the re-rating levers, but management's guidance credibility is under pressure.
🚨 Where they disagree. PE at 83rd percentile of 10-year range — NEAR_PEAK cycle signal. Current PE 14.7x is above the 10Y median of 11.2x (ratio 1.23x) with INFLECTION_UP YoY trend. DII buying is the institutional signal per pe_pb_expansion_snapshots. The stock is not a valuation play — it needs earnings acceleration to justify the multiple. Trough PE of 6.9x (Sep 2019) and peak of 15.9x (Dec 2017) define the cycle band.
What is proven. A small-cap formulator transitioning from Africa-led exports to regulated markets — Cepha block and Health Canada SRA are the re-rating levers, but management's guidance credibility is under pressure.
What is not proven yet. EBITDA margin target cut 20-22% → 15-18%; TGA market entry failed and restarted; Cepha Rs 55-65 Cr → Rs 45 Cr — three material revisions in two years erode conviction.
The test written in advance. Management Guidance Credibility — Three Consecutive Misses — Management Guidance Credibility — Three Consecutive Misses Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement by the next result.
The test written in advance. OPM Structural Compression — No Recovery Signal — OPM Structural Compression — No Recovery Signal FY26 full-year OPM — must stay above 14.5%; Cepha block OPM contribution in FY27 calls by the next result.
The test written in advance. Revenue Growth Below 15-18% Long-Term Target — Revenue Growth Below 15-18% Long-Term Target FY27 H1 revenue — must show >15% YoY to confirm acceleration; Cepha block quarterly disclosures by the next result.
What the company does. FY26 9M revenue Rs 483 Cr (+6.2% YoY) running below 15-18% target; PAT recovery in Q3 (+37.7% YoY to Rs 29 Cr) is promising but driven partly by non-operating income (FX, secured loans). Cephalosporin block ahead of break-even with Rs 32-34 Cr achieved in 9M FY26 against Rs 45 Cr full-year target; FY27 guide Rs 90-100 Cr is the key re-rating lever. Health Canada 6-line SRA approval unlocks 80+ regulated and semi-regulated markets; three management consistency failures since May 2024 keep the stock on WATCH rather than DEPLOY.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Cephalosporin Block Revenue Ramp | HIGH | — | Separate Cepha facility crossed break-even ahead of schedule; Rs 32-34 Cr in 9M FY26 vs Rs 45 Cr full-year target; FY27 guide Rs… | Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement |
| Health Canada SRA — Regulated Market Unlock | MEDIUM_HIGH | — | 6 manufacturing lines approved by Health Canada; $4-5M current Canada revenue targeting $10-15M; SRA credential enables 80+… | Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement |
| Geographical Expansion — 60 to 90 Countries | MEDIUM | — | Africa 40% of exports (resilient collection); Latin America + Southeast Asia 25%; Canada scaling; EU reinspection targeted… | Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement |
| CDMO/CMO Contracts Commercializing | MEDIUM | — | 5 CDMO/CMO contracts signed + 18-19 in process across regulated markets; positioned as incremental bonus revenue toward Rs 1,000… | Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement |
| Non-Operating Income as Earnings Buffer | MEDIUM | — | ~50% of 9M FY26 EBITDA from FX gains, secured loans at 12%+, FDs/mutual funds — structurally elevates reported PAT above… | Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement |
Lever 1 · Operating leverage — BUILDING. Separate Cepha facility crossed break-even ahead of schedule; Rs 32-34 Cr in 9M FY26 vs Rs 45 Cr full-year target; FY27 guide Rs 90-100 Cr is doubling — if regulatory approvals come through. What proves it keeps working: Cephalosporin Block Revenue Ramp. It stops working if Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement.
Lever 2 · Value-added mix — BUILDING. 6 manufacturing lines approved by Health Canada; $4-5M current Canada revenue targeting $10-15M; SRA credential enables 80+ market access indirectly. What proves it keeps working: Health Canada SRA — Regulated Market Unlock. It stops working if Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement.
Lever 10 · New geographies — BUILDING. Africa 40% of exports (resilient collection); Latin America + Southeast Asia 25%; Canada scaling; EU reinspection targeted May-June 2026; expanding from 60 to 90 countries. What proves it keeps working: Geographical Expansion — 60 to 90 Countries. It stops working if Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement.
Lever 5 · Regulatory approval — BUILDING. 5 CDMO/CMO contracts signed + 18-19 in process across regulated markets; positioned as incremental bonus revenue toward Rs 1,000 Cr FY28 target. What proves it keeps working: CDMO/CMO Contracts Commercializing. It stops working if Q4 FY26 PAT ex non-operating income — must exceed Rs 15 Cr to demonstrate trend improvement.
Sources: our stock research file (17 May 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Lincoln Pharmaceuticals Ltd reported ₹177 Cr of revenue in the Jun 26 quarter, +14.9% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 5.3% a year. The last full year, FY26, came in at ₹671 Cr. The last four reported quarters add to ₹693 Cr.
Why this happened. Export is 70% of Lincoln's revenue, with Africa the largest market at 40% of export revenue (~Rs 160 Cr). Despite geopolitical risks, management reports resilient cash collection with only 10-15 day payment delays. Lincoln-owned registrations are replacing partner products across Latin America and Southeast Asia — a margin-accretive transition. EU reinspection is targeted for May-June 2026 with a QP audit already cleared and 3 products filed. Australia TGA strategy restarted after acquisition failure — now filing own products from scratch (12-month delay). The geographic diversification reduces Africa concentration risk over time.
FY26 revenue came in at ₹671 Cr (+7.7% on the year), capping 10 years at 5.3% compound. The latest quarter (Jun 26) printed ₹177 Cr, +14.9% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.1% growth against the decade's 5.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +10.0% over the last 4 quarters against +8.3%/yr over the last 8 — stabilising; TTM profit +11.5% vs −1.0%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Lincoln Pharmaceuticals Ltd's operating margin is 15.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 21.0%. The current quarter sits inside that band.
Why this happened. The Cephalosporin block is the most tangible structural catalyst for Lincoln. The facility is operational with injectables and tablets in commercial production. Management reports Rs 32-34 Cr achieved in the first 9 months of FY26, tracking toward the Rs 45 Cr full-year target. For FY27, the guidance is Rs 90-100 Cr — a near-doubling — with an ultimate capacity of Rs 150-220 Cr at full utilization. The key constraint is regulatory approvals: 'a lot of regulatory has to come' per management. The dedicated R&D center (launching Apr-May 2026) should accelerate dossier development for regulated market submissions. Note: the original FY25 target for this block was Rs 55-65 Cr — the current Rs 45…
The latest quarter's operating margin is 15.0%, +0.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–21.0%.
Why the margin moved: operating margin went +0.0 pp year on year while gross margin went −3.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Lincoln Pharmaceuticals Ltd earned ₹36.0 Cr of net profit in the Jun 26 quarter, +28.6% year on year. Full-year FY26 profit was ₹88.0 Cr. The 10-year compound rate is 13.9%. That is 20.3% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.
Jun 26 profit was ₹36.0 Cr, +28.6% year on year. On the full year, FY26 printed ₹88.0 Cr (+7.3%), and the 10-year compound rate is 13.9%.
Why profit moved: revenue contributed +14.9% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +10.9% vs revenue +10.1%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 100% of Lincoln Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹106 Cr of operating cash against ₹88.0 Cr of profit. After ₹24.0 Cr of capital spending, ₹82.0 Cr was left as free cash.
FY26: operating cash of ₹106 Cr against reported profit of ₹88.0 Cr, leaving free cash of ₹82.0 Cr after ₹24.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 100% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 100%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Lincoln Pharmaceuticals Ltd's cash conversion cycle runs 82 days in FY26, up from 78 days in FY21. Capital spending ran ₹76.0 Cr over the last 3 years. At FY26 sales of ₹671 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹151 Cr sits inside the business at any moment.
FY26: debtors at 88 days, inventory at 94 days — roughly 3.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 82 days, looser than FY21's 78.
The full loop: cash goes out to suppliers and production on day 0; stock waits 94 days to sell; customers pay about 88 days after that; and suppliers themselves are paid at 100 days — netting out to the 82-day cycle.
In money terms: at FY26 sales of ₹671 Cr, each day of the cycle holds about ₹1.8 Cr — so the 82-day loop keeps roughly ₹151 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹76.0 Cr over the last 3 fiscal years against ₹38.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Lincoln Pharmaceuticals Ltd earns a ROCE of 16% in FY26. That is up from a trough of 11% in FY14. Return on invested capital clears the cost of that capital by +0.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.1% net margin on 0.75× asset turns.
FY26 ROCE is 16%, recovered from a FY14 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.1% net margin × 0.75× asset turns × 1.17× balance-sheet leverage ≈ 11.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 12.6% − 12.0% = a +0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Lincoln Pharmaceuticals Ltd carries total debt of ₹4.0 Cr against shareholder equity of ₹758 Cr as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹4.0 Cr against shareholder equity of ₹758 Cr — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Lincoln Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.2 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.6 points over 8 quarters to 4.6%; Domestic institutions: +0.2 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 49.8%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Lincoln Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
Why this happened. Management describes 24-25 CDMO projects that are commercializing across multiple regulated markets. Five contracts are signed; 18-19 more are in various stages of process. The Health Canada SRA credential is the anchor that makes this pipeline viable. Management explicitly frames CDMO as a 'bonus' on top of organic growth — suggesting the Rs 1,000 Cr FY28 target could be achievable 'with' rather than 'from' CDMO. The R&D center launching Apr-May 2026 should accelerate dossier development for regulated market submissions.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Lincoln Pharmaceuticals Ltd trades at 13.0× P/E, mid-range by its own standards (69th percentile). Its long-run median P/E is 11.2×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.0× is mid-range by its own standards (69th percentile), against a long-run median of 11.2× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +6.7% against a +12.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +9.4%/yr price move, ~+8.4%/yr came from earnings growth and ~+1.0 pp from the multiple (expanding); over 10y, of the +10.1%/yr price move, ~+10.7%/yr came from earnings growth and ~−0.6 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Lincoln Pharmaceuticals Ltd was paying for profit growth of about 6.1% a year. Profit itself has compounded 13.9% a year over the past 10 years. Today the market pays 13.0× P/E, the 69th percentile of its own 11-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Lincoln Pharmaceuticals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −12.1% at the trough to +11.5%, a 3-quarter improving streak, ROCE slipping at 16.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.7% | +9.6% | +9.6% | +5.3% |
| Profit | +7.3% | +6.4% | +7.3% | +13.9% |
| EPS | +6.7% | +6.4% | +7.1% | +11.7% |
| Share price | +12.5% | +5.5% | +9.4% | +10.1% |
4-Factor Sector Score
46.8/100 — rank 22 of 44 in Pharma - Formulators · 87% evidence confidence
Lincoln Pharmaceuticals Ltd scores 46.8 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 22. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 15.1 + 15.3 + 10.8 + 5.6 = 46.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Lincoln Pharmaceuticals Ltd's management promised, set against what actually arrived — 3 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
🚨 EBITDA Margin Guidance Downgrade · 18 February 2026. In May 2024, management set a clear margin expectation of 20-22%, framing it as the target they were managing expenses towards. By February 2026, this guidance was significantly lowered to 15-18%, with management characterizing 15% as 'ideal' and 'safe,' representing a material compression in profitability expectations. Earlier call (May 2024): “margins you are expecting also around somewhere between 20 to 22. Between 20 to 22, that”. Later call (Feb 2026): “To be on the safe side, 15% would be ideal, but we might reach 15-18%. That is what we can expect. I don”.
🚨 Australia (TGA) Market Entry Delay · 18 February 2026. The May 2024 call indicated immediate readiness to enter the Australian market, citing possession of necessary certificates. However, the February 2026 call reveals a failed attempt to acquire product authorizations (MAs), forcing a restart of the filing process and delaying the timeline by 'another year or so.' Earlier call (May 2024): “now we are in plan with Australia also according to the guideline of TGA since we have the TGA... So, we can do that now”. Later call (Feb 2026): “we could not successfully transfer those products to our commercial angle. Now we are in a process where we have to file our own products from the start. That will take another year or so for us to start the TGA business.”
🚨 Cephalosporin Revenue Target Reduction · 18 February 2026. In May 2024, management guided for 55-65 crores in revenue from the Cephalosporin block for the immediate year. Nearly two years later in February 2026, the target for the current year has effectively shrunk to 45 crores, indicating a failure to ramp up utilization as originally projected. Earlier call (May 2024): “we are expecting this year at least to touch around INR55 crores to INR60 crores to INR65 crores of business from that particular factory.” Later call (Feb 2026): “By the end of this year, we are expecting revenue between 45 crores from that block. About 32-34 crores of that is already done.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 73.7/100Favorable setup82% evidence | LEADER | 31.1/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 17.8/25 ROCE 24.1% · OPM 25% 76% evidence | 6.2/20 P/E 46.3× · PEG — 50% evidence | 18.6/20 RS sector 72.7% · RS bench 113.3% · 1Y 288.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.1 + 17.8 + 6.2 + 18.6 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 71.1/100Favorable setup100% evidence | TURNING | 30.8/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 39.8% · OPM 20% 100% evidence | 12.4/20 P/E 21.9× · PEG 1.43 100% evidence | 9.7/20 RS sector -11.1% · RS bench 15.2% · 1Y 17.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 18.2 + 12.4 + 9.7 = 71.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Bliss GVS Pharma LtdBLISSGVS | 69.5/100Favorable setup82% evidence | LEADER | 29.0/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 14.8/25 ROCE 16.9% · OPM 27% 76% evidence | 6.0/20 P/E 55.7× · PEG — 50% evidence | 19.7/20 RS sector 102.4% · RS bench 147.9% · 1Y 362.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 14.8 + 6 + 19.7 = 69.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ipca Laboratories LtdIPCALAB | 67.9/100Favorable setup82% evidence | BREAKING OUT | 26.3/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.8/25 ROCE 17% · OPM 24% 76% evidence | 11.0/20 P/E 36.4× · PEG — 50% evidence | 14.8/20 RS sector -0.6% · RS bench 28.3% · 1Y 47.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.8 + 11 + 14.8 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Lupin LtdLUPIN | 66.8/100Favorable setup93% evidence | ASLEEP | 29.6/35 Revenue 28.2% · PAT 49.2% · OPM change 2 pp 100% evidence | 19.3/25 ROCE 29.9% · OPM 30% 100% evidence | 16.3/20 P/E 16.1× · PEG 0.54 65% evidence | 1.6/20 RS sector -26.2% · RS bench -4% · 1Y 7.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.6 + 19.3 + 16.3 + 1.6 = 66.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.2% and the one-year return is 7.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 66.3/100Favorable setup75% evidence | LEADER | 27.3/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.2/25 ROCE 24% · OPM 21% 76% evidence | 9.9/20 P/E 36.4× · PEG — 15% evidence | 10.9/20 RS sector -2.5% · RS bench 25.5% · 1Y 44.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27.3 + 18.2 + 9.9 + 10.9 = 66.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Corona Remedies LtdCORONA | 65.2/100Favorable setup73% evidence | BREAKING OUT | 23.0/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.8/20 P/E 64.4× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23 + 20.4 + 11.8 + 10 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Fredun Pharmaceuticals LtdFREDUN | 64.9/100Mixed-positive evidence74% evidence | 26.7/35 Revenue 91.5% · PAT 100% · OPM change 0 pp 95% evidence | 13.0/25 ROCE 21.3% · OPM 14% 95% evidence | 9.3/20 P/E 53.3× · PEG — 15% evidence | 15.9/20 RS sector 24.1% · RS bench 96.2% · 1Y 9.2%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 26.7 + 13 + 9.3 + 15.9 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Accent Microcell LtdACCENTMIC | 64.5/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 18.9/25 ROCE 24.9% · OPM 16% 95% evidence | 8.7/20 P/E 39.7× · PEG — 50% evidence | 19.4/20 RS sector 44.8% · RS bench 83.4% · 1Y 160.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 18.9 + 8.7 + 19.4 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Caplin Point Laboratories LtdCAPLIPOINT | 61.8/100Mixed-positive evidence100% evidence | LEADER | 19.0/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 17.7/25 ROCE 24.2% · OPM 35% 100% evidence | 9.4/20 P/E 31.5× · PEG 1.52 100% evidence | 15.7/20 RS sector 5.8% · RS bench 36.1% · 1Y 28.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 17.7 + 9.4 + 15.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rubicon Research LtdRUBICON | 57.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 24.1/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 17.9/25 ROCE 28.4% · OPM 24% 100% evidence | 5.6/20 P/E 105× · PEG 2.63 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 24.1 + 17.9 + 5.6 + 10 = 57.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Marksans Pharma LtdMARKSANS | 57.4/100Mixed-positive evidence87% evidence | BREAKING OUT | 25.8/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 15.8/25 ROCE 18.8% · OPM 25% 100% evidence | 6.3/20 P/E 28.9× · PEG 2.85 65% evidence | 9.5/20 RS sector -18.1% · RS bench 58.3% · 1Y 95%11 of 11 weeks ahead 70% evidence |
| Exact sum: 25.8 + 15.8 + 6.3 + 9.5 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Ajanta Pharma LtdAJANTPHARM | 56.3/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.3/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 19.6/25 ROCE 34.5% · OPM 26% 100% evidence | 5.5/20 P/E 38.9× · PEG 2.31 100% evidence | 9.9/20 RS sector -5.3% · RS bench 22.1% · 1Y 35.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 19.6 + 5.5 + 9.9 = 56.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Strides Pharma Science LtdSTAR | 55.9/100Mixed-positive evidence75% evidence | TURNING | 20.6/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.3/25 ROCE 18.3% · OPM 18% 76% evidence | 11.2/20 P/E 18.8× · PEG — 15% evidence | 10.8/20 RS sector -4.1% · RS bench 24% · 1Y 32.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.3 + 11.2 + 10.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Wockhardt LtdWOCKPHARMA | 54.3/100Mixed-positive evidence74% evidence | TURNING | 24.9/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.3/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 88.8× · PEG — 15% evidence | 15.3/20 RS sector 10.9% · RS bench 42% · 1Y 47.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 5.3 + 8.8 + 15.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 52.6/100Mixed-positive evidence93% evidence | LEADER | 11.9/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.5/25 ROCE 25.7% · OPM 22% 100% evidence | 11.1/20 P/E 38.2× · PEG 1.43 65% evidence | 12.1/20 RS sector -8.1% · RS bench 19.1% · 1Y 13.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 17.5 + 11.1 + 12.1 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ERIS Lifesciences LtdERIS | 52.6/100Mixed-positive evidence76% evidence | BASING | 20.4/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.3/25 ROCE 14.1% · OPM 34% 76% evidence | 11.9/20 P/E 28.6× · PEG — 50% evidence | 6.0/20 RS sector -13.8% · RS bench -5% · 1Y -21.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 14.3 + 11.9 + 6 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Akums Drugs & Pharmaceuticals LtdAKUMS | 51.3/100Mixed-positive evidence75% evidence | LEADER | 13.2/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.9/25 ROCE 14.9% · OPM 15% 76% evidence | 9.6/20 P/E 40× · PEG — 15% evidence | 17.6/20 RS sector 15.9% · RS bench 48% · 1Y 68.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 10.9 + 9.6 + 17.6 = 51.3 · Decision use: Price leads the evidence: RS versus the benchmark is 48%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Suven Life Sciences LtdSUVEN | 51.0/100Mixed-positive evidence67% evidence | LEADER | 19.8/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.2/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.0/20 RS sector 29.3% · RS bench 63% · 1Y 60%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 2.2 + 10 + 19 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Zydus Lifesciences LtdZYDUSLIFE | 49.3/100Mixed-negative evidence100% evidence | FADING | 11.9/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.7/25 ROCE 21.1% · OPM 24% 100% evidence | 13.7/20 P/E 22.9× · PEG 1.23 100% evidence | 7.0/20 RS sector -11.7% · RS bench 14.3% · 1Y 10.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 16.7 + 13.7 + 7 = 49.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 10.6/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.6/25 ROCE 25.4% · OPM 22% 100% evidence | 3.9/20 P/E 53.8× · PEG 2.34 100% evidence | 12.0/20 RS sector -0.3% · RS bench 23.5% · 1Y 40.2%3 of 4 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 10.6 + 20.6 + 3.9 + 12 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 22Lincoln Pharmaceuticals Ltdthis pageLINCOLN | 46.8/100Mixed-negative evidence87% evidence | ASLEEP | 15.1/35 Revenue 10% · PAT 11.5% · OPM change 0 pp 95% evidence | 15.3/25 ROCE 16.3% · OPM 15% 95% evidence | 10.8/20 P/E 13× · PEG — 50% evidence | 5.6/20 RS sector -15.1% · RS bench 9.9% · 1Y 11.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 15.3 + 10.8 + 5.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Alkem Laboratories LtdALKEM | 45.1/100Mixed-negative evidence82% evidence | ASLEEP | 14.6/35 Revenue 13.4% · PAT -5.5% · OPM change -2 pp 95% evidence | 17.4/25 ROCE 21.2% · OPM 20% 76% evidence | 11.6/20 P/E 26.8× · PEG — 50% evidence | 1.5/20 RS sector -28.5% · RS bench -6.5% · 1Y -4.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 17.4 + 11.6 + 1.5 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Aurobindo Pharma LtdAUROPHARMA | 44.8/100Mixed-negative evidence100% evidence | LEADER | 16.5/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.3/25 ROCE 12.9% · OPM 21% 100% evidence | 4.8/20 P/E 25.6× · PEG 2.67 100% evidence | 11.2/20 RS sector -1.3% · RS bench 26.9% · 1Y 60.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.3 + 4.8 + 11.2 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Sun Pharmaceutical Industries LtdSUNPHARMA | 44.2/100Mixed-negative evidence100% evidence | TURNING | 16.9/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 17.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.3/20 P/E 35× · PEG 3.8 100% evidence | 5.7/20 RS sector -19.4% · RS bench 4.7% · 1Y 15.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 17.3 + 4.3 + 5.7 = 44.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Kilitch Drugs (India) LtdKILITCH | 44.1/100Mixed-negative evidence87% evidence | FADING | 13.9/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.2/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.2/20 P/E 21.6× · PEG — 50% evidence | 6.8/20 RS sector -15.6% · RS bench 10% · 1Y 0.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 9.2 + 14.2 + 6.8 = 44.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27Gufic BioSciences LtdGUFICBIO | 44.0/100Mixed-negative evidence94% evidence | BREAKING OUT | 23.1/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 9.8/25 ROCE 12.3% · OPM 18% 100% evidence | 2.3/20 P/E 58× · PEG 4.78 100% evidence | 8.8/20 RS sector -18.4% · RS bench 26.1% · 1Y 19.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 23.1 + 9.8 + 2.3 + 8.8 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Alembic Pharmaceuticals LtdAPLLTD | 43.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 16.4/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.4/25 ROCE 12.6% · OPM 15% 100% evidence | 12.5/20 P/E 21.4× · PEG 1.74 100% evidence | 6.4/20 RS sector -24.1% · RS bench 1.5% · 1Y -14.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 16.4 + 8.4 + 12.5 + 6.4 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Amrutanjan Health Care LtdAMRUTANJAN | 43.2/100Mixed-negative evidence87% evidence | BASING | 13.2/35 Revenue 10.7% · PAT -1.1% · OPM change -2.9 pp 95% evidence | 14.9/25 ROCE 24.8% · OPM 6.1% 95% evidence | 14.3/20 P/E 22.8× · PEG — 50% evidence | 0.8/20 RS sector -37.2% · RS bench -17% · 1Y -36.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 14.9 + 14.3 + 0.8 = 43.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Mankind Pharma LtdMANKIND | 42.9/100Mixed-negative evidence100% evidence | BASING | 16.8/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 13.8/25 ROCE 13.5% · OPM 26% 100% evidence | 8.2/20 P/E 44.2× · PEG 2.81 100% evidence | 4.1/20 RS sector -22.9% · RS bench 0.4% · 1Y -10.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 13.8 + 8.2 + 4.1 = 42.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31FDC LtdFDC | 41.9/100Mixed-negative evidence94% evidence | ASLEEP | 12.8/35 Revenue 3.5% · PAT 8.2% · OPM change -1 pp 100% evidence | 12.9/25 ROCE 15.4% · OPM 21% 100% evidence | 11.9/20 P/E 18× · PEG 2 100% evidence | 4.3/20 RS sector -25.1% · RS bench -11.7% · 1Y -27.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.9 + 11.9 + 4.3 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Indoco Remedies LtdINDOCO | 40.7/100Thin evidence · provisional58% evidence | TURNING | 20.2/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.4/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.1/20 RS sector -32.2% · RS bench 14.2% · 1Y -3.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.2 + 4.4 + 10 + 6.1 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Zim Laboratories LtdZIMLAB | 39.9/100Mixed-negative evidence79% evidence | LEADER | 9.6/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.1/25 ROCE 4.8% · OPM 2.6% 95% evidence | 5.8/20 P/E 202× · PEG — 50% evidence | 18.4/20 RS sector 25.7% · RS bench 59.5% · 1Y 87.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 6.1 + 5.8 + 18.4 = 39.9 · Decision use: Price leads the evidence: RS versus the benchmark is 59.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Torrent Pharmaceuticals LtdTORNTPHARM | 39.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.6/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.8/20 P/E 84.6× · PEG 5.11 100% evidence | 8.2/20 RS sector -7.4% · RS bench 19.5% · 1Y 39%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 14.2 + 0.8 + 8.2 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Bafna Pharmaceuticals LtdBAFNAPH | 39.8/100Mixed-negative evidence60% evidence | TURNING | 11.5/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.7/20 P/E 91.5× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 84.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 11.5 + 7.3 + 8.7 + 12.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 37.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 9.8/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.3/25 ROCE 11.5% · OPM 17% 95% evidence | 11.9/20 P/E 20× · PEG — 50% evidence | 5.8/20 RS sector -29.8% · RS bench -7.1% · 1Y -22.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 10.3 + 11.9 + 5.8 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Natco Pharma LtdNATCOPHARM | 37.3/100Mixed-negative evidence100% evidence | ASLEEP | 3.0/35 Revenue -20.8% · PAT -32.5% · OPM change -18 pp 100% evidence | 14.1/25 ROCE 17.4% · OPM 25% 100% evidence | 19.1/20 P/E 12.8× · PEG 0.76 100% evidence | 1.1/20 RS sector -31.6% · RS bench -10.9% · 1Y -4.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 14.1 + 19.1 + 1.1 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 38Biocon LtdBIOCON | 36.2/100Mixed-negative evidence100% evidence | ASLEEP | 13.3/35 Revenue 9.8% · PAT -36.4% · OPM change 1 pp 100% evidence | 7.7/25 ROCE 3.6% · OPM 20% 100% evidence | 11.5/20 P/E 87.5× · PEG 0.82 100% evidence | 3.7/20 RS sector -22.1% · RS bench 1.3% · 1Y 7.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 7.7 + 11.5 + 3.7 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Bharat Parenterals LtdBPLPHARMA | 35.8/100Thin evidence · provisional58% evidence | 12.3/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.1/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.4/20 RS sector -12.8% · RS bench 24.2% · 1Y 10.6%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 12.3 + 4.1 + 10 + 9.4 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Cipla LtdCIPLA | 32.6/100Adverse evidence100% evidence | BASING | 4.6/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 12.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.0/20 P/E 30.8× · PEG 1.25 100% evidence | 3.7/20 RS sector -25.3% · RS bench -2.3% · 1Y -12.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 4.6 + 12.3 + 12 + 3.7 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Dr Reddys Laboratories LtdDRREDDY | 30.1/100Adverse evidence100% evidence | BASING | 3.7/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 11.7/25 ROCE 13% · OPM 11% 100% evidence | 13.3/20 P/E 30.2× · PEG 1.15 100% evidence | 1.4/20 RS sector -28% · RS bench -5.9% · 1Y -8.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 3.7 + 11.7 + 13.3 + 1.4 = 30.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 42Influx Healthtech LtdINFLUX | 59.8/100Thin evidence · provisional50% evidence | TURNING | 19.3/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.8/25 ROCE 40% · OPM 19% 95% evidence | 10.3/20 P/E 30.5× · PEG — 15% evidence | 9.4/20 RS sector -9.8% · RS bench 16% · 1Y 43.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.8 + 10.3 + 9.4 = 59.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Syncom Healthcare LtdSYNCOM | 49.7/100Thin evidence · provisional31% evidence | 17.1/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.7/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.1 + 6.9 + 10 + 15.7 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Sai Parenterals LtdSAIPARENT | 37.4/100Thin evidence · provisional38% evidence | ASLEEP | 13.7/35 Revenue — · PAT — · OPM change -1 pp 32% evidence | 5.1/25 ROCE 5.3% · OPM 13.2% 95% evidence | 8.6/20 P/E 111× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 9 weeks ahead 0% evidence |
| Exact sum: 13.7 + 5.1 + 8.6 + 10 = 37.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Lincoln Pharmaceuticals Ltd's share price today?
Lincoln Pharmaceuticals Ltd trades at ₹624, +12.5% over the past year. The company is valued at ₹1,249 Cr. The stock sits at 61% of its 52-week range of ₹453–₹734, +4.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 26 weeks in. — as of 11 September 2026.
What were Lincoln Pharmaceuticals Ltd's latest quarterly results?
Lincoln Pharmaceuticals Ltd reported revenue of ₹177 Cr and net profit of ₹36.0 Cr for the Jun 26 quarter. Revenue rose 14.9% and profit rose 28.6% year on year. Earnings per share were ₹18.09. The operating margin was 15.0%, 0.0 pp higher than a year earlier. — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's revenue?
Lincoln Pharmaceuticals Ltd reported revenue of ₹177 Cr in the Jun 26 quarter, +14.9% year on year. For the full FY26 fiscal year, revenue was ₹671 Cr (+7.7%). Over the last 10 years revenue compounded at 5.3% a year. — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's profit?
Lincoln Pharmaceuticals Ltd earned ₹36.0 Cr of net profit in the Jun 26 quarter, +28.6% year on year. Full-year FY26 profit was ₹88.0 Cr. The operating margin ran 15.0% in the latest quarter. — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's market cap?
Lincoln Pharmaceuticals Ltd's market capitalisation is ₹1,249 Cr at a share price of ₹624. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's P/E ratio?
Lincoln Pharmaceuticals Ltd trades at a P/E of 13.0×, at the 69th percentile of its own 11-year range, against a long-run median of 11.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Lincoln Pharmaceuticals Ltd pay a dividend?
Yes — Lincoln Pharmaceuticals Ltd's dividend payout was 4% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd overvalued?
On its own history, Lincoln Pharmaceuticals Ltd looks expensive: its P/E of 13.0× sits at the 69th percentile of its 11-year range (long-run median 11.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd growing?
Yes — Lincoln Pharmaceuticals Ltd is growing: latest-quarter revenue +14.9% year on year, profit +28.6%, and the margin +0.0 pp at 15.0%. The 10-year compound rates are 5.3% (revenue) and 13.9% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Lincoln Pharmaceuticals Ltd performing?
Lincoln Pharmaceuticals Ltd is in a confirmed uptrend, 26 weeks in. Its latest quarter's revenue rose 14.9% and profit rose 28.6% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Lincoln Pharmaceuticals Ltd in?
Turning around — profit growth swung from −12.1% at the trough to +11.5%, a 3-quarter improving streak, ROCE slipping at 16.0%. The read comes from the last 12 quarters of growth (revenue growth +10.0% latest, profit growth +11.5% latest, eps growth +11.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 26 of stage 2), trading +4.2% versus its 200-day average and at 61% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd beating the market?
On recent form, yes — Lincoln Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +321% against the NIFTY 500's +273% — ahead of the index over the full window. — as of 11 September 2026.
Will Lincoln Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Lincoln Pharmaceuticals Ltd. What it measures instead: the share price is ₹624, the price is in a confirmed uptrend 26 weeks in. Its P/E of 13.0× sits at the 69th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Lincoln Pharmaceuticals Ltd?
Promoters hold 49.8% of Lincoln Pharmaceuticals Ltd, foreign institutions 4.6%, domestic institutions 0.3% and the public 45.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Lincoln Pharmaceuticals Ltd have too much debt?
No — Lincoln Pharmaceuticals Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 98×. FY26 borrowings were ₹4.0 Cr against equity of ₹758 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's capex?
Lincoln Pharmaceuticals Ltd spent ₹76.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹24.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Lincoln Pharmaceuticals Ltd's cash flow?
Lincoln Pharmaceuticals Ltd generated ₹106 Cr of operating cash flow in FY26 and ₹82.0 Cr of free cash flow after ₹24.0 Cr of capital spending. Reported profit that year was ₹88.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 100% of Lincoln Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹106 Cr against reported profit of ₹88.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Lincoln Pharmaceuticals Ltd in its business cycle?
Lincoln Pharmaceuticals Ltd's FY26 operating margin was 15.0%, against a 13-year band of 10.0%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Lincoln Pharmaceuticals Ltd's price assume?
At its price on 13 June 2026, Lincoln Pharmaceuticals Ltd was priced for profit growth of about 6.1% a year. Profit itself has compounded 13.9% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Lincoln Pharmaceuticals Ltd story?
Biggest watch item: the P/E sits at the 69th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Lincoln Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Lincoln Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!